Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

BACKGROUND: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Respir Res
Main Authors: Jouneau, Stéphane, Crestani, Bruno, Thibault, Ronan, Lederlin, Mathieu, Vernhet, Laurent, Valenzuela, Claudia, Wijsenbeek, Marlies, Kreuter, Michael, Stansen, Wibke, Quaresma, Manuel, Cottin, Vincent
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690188/
https://ncbi.nlm.nih.gov/pubmed/33239000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01528-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares